HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-11-18EMA Authorised: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz;emtricitabine;tenofovir disoproxil maleate) — Mylan Pharmaceuticals Limited
EMA has authorised the fixed-dose combination therapy Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan for the treatment of HIV infections…
-
EMA approval · 2025-11-18EMA Authorised: Viread (tenofovir disoproxil fumarate) — Gilead Sciences Ireland UC
The European Medicines Agency authorised Viread (tenofovir disoproxil fumarate) for chronic hepatitis B and HIV infections; the marketing au…
-
EMA approval · 2025-11-17EMA Authorised: Isentress (raltegravir) — Merck Sharp & Dohme B.V.
The EMA has authorised Isentress (raltegravir) for HIV infections; decision dated 12 November 2025.
-
EMA approval · 2025-11-14EMA Authorised: Juluca (dolutegravir sodium;rilpivirine hydrochloride) — ViiV Healthcare B.V.
EMA authorised Juluca, a fixed-dose combination of dolutegravir and rilpivirine, for HIV infections, with ViiV Healthcare B.V. as the market…
-
FDA approval · 2025-10-29FDA Approved: DELSTRIGO — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for DELSTRIGO, a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fuma…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-10-29FDA Approved: PIFELTRO — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for PIFELTRO (doravirine) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2025-10-28FDA Approved: TRIUMEQ PD — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for TRIUMEQ PD (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company.
-
FDA approval · 2025-10-28FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for DOVATO (dolutegravir and lamivudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2025-10-28FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for TRIUMEQ, a fixed-dose combination antiretroviral therapy consisting of abacavir sulfate, dol…
-
FDA approval · 2025-10-28FDA Approved: TIVICAY PD — Supplemental Application (ViiV Healthcare Company)
The FDA issued a supplemental approval for Tivicay PD (dolutegravir) from ViiV Healthcare, adding/changing the pediatric formulation for HIV…
-
FDA approval · 2025-10-28FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approves a supplemental application for Tivicay (dolutegravir) from ViiV Healthcare Company.
-
FDA approval · 2025-10-02FDA Approved: ETRAVIRINE — Original Application (Bionpharma Inc.)
FDA approves the original application for etravirine from Bionpharma Inc., making a generic NNRTI available for HIV-1 infection.
-
EMA approval · 2025-09-11EMA Authorised: Rukobia (fostemsavir trometamol) — ViiV Healthcare B.V.
The European Medicines Agency authorised Rukobia (fostemsavir trometamol) for HIV infections, expanding treatment options for adults with mu…
-
EMA approval · 2025-09-09EMA Authorised: Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan) (tenofovir disoproxil) — Viatris Limited
EMA authorised a new medicinal product containing tenofovir disoproxil for HIV infections, marketed as Tenofovir disoproxil Viatris by Viatr…
-
EMA approval · 2025-09-08EMA Authorised: Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan) (lopinavir;ritonavir) — Viatris Limited
The European Medicines Agency authorised Lopinavir/Ritonavir Viatris for HIV infections, with Viatris Limited listed as the marketing author…
-
FDA approval · 2025-08-20FDA Approved: LAMIVUDINE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application to authorize lamivudine oral (generic) from Chartwell RX, LLC.
-
EMA approval · 2025-08-13EMA Authorised: Stribild (elvitegravir;cobicistat;emtricitabine;tenofovir disoproxil fumarate) — Gilead Sciences Ireland UC
The EMA authorised Stribild, a fixed-dose combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for HIV …
-
FDA approval · 2025-07-30FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for BIKTARVY, a fixed-dose combination HIV-1 therapy from Gilead Sciences, Inc.
-
FDA approval · 2025-07-23FDA Approved: ATAZANAVIR SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Atazanavir sulfate submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2025-07-18FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Laurus Labs Limited)
The FDA approved a supplemental application for a generic fixed-dose combination emtricitabine/tenofovir disoproxil fumarate by Laurus Labs …
-
EMA approval · 2025-06-30EMA Authorised: Emtricitabine/Tenofovir disoproxil Mylan (emtricitabine;tenofovir disoproxil maleate) — Mylan Pharmaceuticals Limited
EMA authorised Emtricitabine/Tenofovir disoproxil Mylan for HIV infections. It provides a fixed-dose combination option for antiretroviral t…
-
FDA approval · 2025-06-26FDA Approved: ATAZANAVIR SULFATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for atazanavir sulfate (atazanavir) under an ANDA from Aurobindo Pharma Limited.
-
FDA approval · 2025-06-20FDA Approved: DESCOVY — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for DESCOVY (emtricitabine and tenofovir alafenamide) submitted by Gilead, updating the product labe…
-
FDA approval · 2025-06-20FDA Approved: TYBOST — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for TYBOST (cobicistat) submitted by Gilead Sciences.
-
FDA approval · 2025-06-18FDA Approved: YEZTUGO — Original Application (Gilead Sciences, Inc.)
FDA approved YEZTUGO (lenacapavir sodium) from Gilead as an original application for the treatment of HIV-1 infection in adults with multidr…